CoChat

A Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Ipsapirone Versus Lorazepam in Patients With Generalized Anxiety Disorder: A Prospective Multicenter Trial

CUTLER, NEAL R., SRAMEK, JOHN J., KEPPEL HESSELINK, JAN M., KROL, ALICE, ROESCHEN, JULIE, RICKELS, KARL, SCHWEIZER, EDWARD · 1993 · Journal of Clinical Psychopharmacology
Cited by 77

The DOI matches its Crossref record.

Abstract

This multicenter, double-blind, placebo-controlled, randomized study compared the efficacy, safety, and tolerability of ipsapirone (an azapi-rone anxiolytic) at daily dose levels of 10.0 to 30.0 mg with a daily dose of 2.0 to 6.0 mg of lorazepam (a benzodiazepine) or placebo when given to outpatients with generalized anxiety disorder (GAD) of moderate or greater severity. A total of 317 outpatients with a primary diagnosis of GAD according to DSM-III criteria (at least 1 month's duration) were randomized. Study entry criteria at the time of screening and at baseline included a Hamilton Rating Scale for Anxiety (HAM-A) score of 18 or more, a Covi Anxiety Scale score of 8 or more, and a Raskin Depression Scale score of 7 or less. The study design consisted of a 1-week, single-blind placebo evaluation, a 4-week, double-blind acute treatment period, and a 4-week extension period, followed by a 2-week, single-blind placebo withdrawal period. Efficacy was measured by changes in the HAM-A and Clinical Global Impression Scale and by evaluations of the Hamilton Rating Scale for Depression and Zung-Anxiety Self-Rating scale. The Raskin and Covi scales were performed at screening and baseline only. Withdrawal reactions were assessed during the withdrawal period by the Physician Withdrawal Checklist and by a patient self-rating checklist. Two-hundred sixty-three patients were valid for the analysis of efficacy in the ipsapirone (N = 87), lorazepam (N = 89), and placebo (N = 87) groups. Both ipsapirone (mean daily dose, 18.0 mg) and lorazepam (mean daily dose, 3.5 mg) significantly (p & 0.05) reduced HAM-A and Clinical Global Impression scores during the acute treatment phase. Two hundred fifty-four patients completed the acute phase, and 16 patients dropped out of the study because of adverse events (ipsapirone, N = 7; lorazepam, N = 4; and placebo, N = 5) during this phase. Study medication was reduced for 87 patients because of adverse events during the acute phase (ipsapirone, N = 35; lorazepam, N = 35; and placebo, N = 17). A total of nine patients dropped out because of a lack of efficacy in the acute phase (ipsapirone, N = 2; lorazepam, N = 2; placebo, N = 5). The Physician Withdrawal Checklist ratings, performed at weeks 9 and 10, demonstrated greater withdrawal symptoms, such as rebound anxiety, in patients treated with lorazepam as compared with patients on ipsapirone. Both lorazepam and ipsapirone demonstrated significantly more side effects than placebo. Ipsapirone was shown to be equally as effective as lorazepam in the management of GAD, and as a result of fewer withdrawal symptoms, ipsapirone may represent a more rational and selective therapy for GAD. (J Clin Psychopharmacol 1993;13:429–437)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004714-199312000-00009

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 77

Metadata

Authors
CUTLER, N. R., SRAMEK, J. J., KEPPEL HESSELINK, J. M., KROL, A., ROESCHEN, J., RICKELS, K., & SCHWEIZER, E.
Venue
Journal of Clinical Psychopharmacology
Published
1993-12
Volume
13
Issue
6
Pages
429???437
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1993794887
Cited by
77
References
0
FWCI
4.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Ipsapirone Versus Lorazepam in Patients With Generalized Anxiety Disorder: A Prospective Multicenter Trial. https://app.cochat.ai/papers/10.1097/00004714-199312000-00009
The paper
CUTLER, N. R., SRAMEK, J. J., KEPPEL HESSELINK, J. M., KROL, A., ROESCHEN, J., RICKELS, K., & SCHWEIZER, E. (1993). A Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Ipsapirone Versus Lorazepam in Patients With Generalized Anxiety Disorder: A Prospective Multicenter Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199312000-00009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.